Christa L Frassetto from Castle Rock, CO, age 44

Christa Frassetto Phones & Addresses

Castle Rock, CO
4344 Dexter St, Philadelphia, PA 19128
Wayne, PA
Columbia, SC
Cayce, SC
Lake in the Hills, IL
Beaumont, TX
Port Arthur, TX
Algonquin, IL
Cheyenne, WY
San Antonio, TX

Work

Company:

Emerson resources
Jan 2010
Position:

Group leader, formulation development

Education

Degree:

M.E.
School / High School:

University of South Carolina-Columbia
2003 to 2005
Specialities:

Chemical Engineering

Skills

Formulation • Technology Transfer • Gmp • Drug Delivery • Sop

Industries

Pharmaceuticals

Resumes

Senior Manager, Formulation Development

view source

Location:

Norristown, PA

Industry:

Pharmaceuticals

Work:

Emerson Resources since Jan 2010
Group Leader, Formulation Development
Emerson Resources Aug 2005 - Jan 2010
Senior Formulation Scientist
DuPont 2000 - 2003
Engineering Co-op

Education:

University of South Carolina-Columbia 2003 - 2005
M.E., Chemical Engineering Lamar University 1998 - 2003
BS, Chemical Engineering

Skills:

Formulation
Technology Transfer
Gmp
Drug Delivery
Sop

Us Patents

Anhydrous Crystalline Free Base Form Of 6--3-Ethoxy-1,2-Benzisoxazole
view source
US Patent:

20160194310, Jul 7, 2016
Filed:

Jun 19, 2015
Appl. No.:

14/916373
Inventors:

- Alpharetta GA, US
David MCALLISTER - Notting Hill, AU
Andrew TRIGWELL - Notting Hill, AU
Robert Vincent TUOHY - Norristown PA, US
Peter SNYDER, JR. - Norristown PA, US
Christa Leisa FRASSETTO - Norristown PA, US
International Classification:

C07D 413/14
A61K 9/10
A61K 9/20
A61K 47/12
A61K 47/36
A61K 47/26
A61K 47/14
A61K 47/10
A61K 31/501
A61K 47/38
Abstract:

A crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is provided which is useful in the treatment of infections caused by Picornaviridae such as human rhinovirus (HRV), and in particular the crystal form is an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, a method of manufacturing the free base crystalline form is also provided, including a step of micronizing the compound particles, optionally using a wetting agent, as well as pharmaceutical compositions incorporating the free base crystalline form such as tablets or suspensions, and methods of therapeutic treatments using this form and pharmaceutical compositions thereof.

Christa L Frassetto